https://respiratorytrials.org/ A curated, verified index of the trials that underpin respiratory practice. Every citation is checked against PubMed. en-GB Thu, 06 Aug 2026 08:23:32 +0000 https://respiratorytrials.org/trial/teton-2/ https://respiratorytrials.org/trial/teton-2/ Interstitial lung disease Inhaled treprostinil slowed FVC decline in IPF, in patients mostly already on antifibrotics https://respiratorytrials.org/trial/abra/ https://respiratorytrials.org/trial/abra/ Asthma A single dose of benralizumab at the time of an eosinophilic exacerbation beat prednisolone https://respiratorytrials.org/trial/aspen/ https://respiratorytrials.org/trial/aspen/ Bronchiectasis Brensocatib cut exacerbations by about 20% — the first drug licensed specifically for bronchiectasis https://respiratorytrials.org/trial/clear/ https://respiratorytrials.org/trial/clear/ Bronchiectasis Neither hypertonic saline nor carbocisteine reduced exacerbations in bronchiectasis https://respiratorytrials.org/trial/fibroneer-ild/ https://respiratorytrials.org/trial/fibroneer-ild/ Interstitial lung disease Nerandomilast slowed FVC decline in progressive pulmonary fibrosis, including on top of nintedanib https://respiratorytrials.org/trial/fibroneer-ipf/ https://respiratorytrials.org/trial/fibroneer-ipf/ Interstitial lung disease Nerandomilast slowed FVC decline on top of existing antifibrotics — the first genuinely additive agent in IPF https://respiratorytrials.org/trial/matinee/ https://respiratorytrials.org/trial/matinee/ COPD Mepolizumab reduced exacerbations by 21% in eosinophilic COPD on triple therapy, without improving symptoms https://respiratorytrials.org/trial/peerless/ https://respiratorytrials.org/trial/peerless/ Pulmonary embolism Mechanical thrombectomy beat catheter-directed lysis on a composite driven by less ICU use, with no mortality difference https://respiratorytrials.org/trial/predmeth/ https://respiratorytrials.org/trial/predmeth/ Interstitial lung disease Methotrexate matched prednisone as first-line treatment for pulmonary sarcoidosis, with a different side-effect profile https://respiratorytrials.org/trial/renove/ https://respiratorytrials.org/trial/renove/ Pulmonary embolism Reduced-dose anticoagulation failed formal non-inferiority for recurrence but bled much less https://respiratorytrials.org/trial/skyline/ https://respiratorytrials.org/trial/skyline/ Cystic fibrosis The once-daily triple matched the twice-daily standard on lung function https://respiratorytrials.org/trial/zenith/ https://respiratorytrials.org/trial/zenith/ Pulmonary hypertension Sotatercept cut death, transplant or hospitalisation by three quarters in high-risk PAH https://respiratorytrials.org/trial/promis/ https://respiratorytrials.org/trial/promis/ Bronchiectasis Inhaled colistimethate reduced exacerbations in one trial and not in its replicate https://respiratorytrials.org/trial/redox/ https://respiratorytrials.org/trial/redox/ COPD 24 hours a day of oxygen was no better than 15 in severe hypoxaemia https://respiratorytrials.org/trial/surmount-osa/ https://respiratorytrials.org/trial/surmount-osa/ Sleep medicine Tirzepatide halved the apnoea-hypopnoea index in obese patients with OSA https://respiratorytrials.org/trial/swift/ https://respiratorytrials.org/trial/swift/ Asthma Two injections a year roughly halved exacerbations in eosinophilic severe asthma https://respiratorytrials.org/trial/boreas/ https://respiratorytrials.org/trial/boreas/ COPD Dupilumab cut exacerbations by 30% in eosinophilic COPD already on triple therapy https://respiratorytrials.org/trial/calgb-140503/ https://respiratorytrials.org/trial/calgb-140503/ Lung cancer Sublobar resection matched lobectomy for small peripheral node-negative lung cancers https://respiratorytrials.org/trial/cape-cod/ https://respiratorytrials.org/trial/cape-cod/ Pneumonia Hydrocortisone roughly halved 28-day mortality in severe community-acquired pneumonia https://respiratorytrials.org/trial/enhance/ https://respiratorytrials.org/trial/enhance/ COPD Ensifentrine improved lung function in both replicate trials and reduced exacerbations, with placebo-level tolerability https://respiratorytrials.org/trial/ever-ild/ https://respiratorytrials.org/trial/ever-ild/ Interstitial lung disease Adding rituximab to mycophenolate improved lung function in NSIP-pattern ILD, with more viral infection https://respiratorytrials.org/trial/simplify/ https://respiratorytrials.org/trial/simplify/ Cystic fibrosis Patients on triple modulator therapy could stop hypertonic saline or dornase alfa without losing lung function https://respiratorytrials.org/trial/epic-hr/ https://respiratorytrials.org/trial/epic-hr/ COVID-19 Nirmatrelvir-ritonavir cut hospitalisation or death by 89% in unvaccinated high-risk outpatients https://respiratorytrials.org/trial/mandala/ https://respiratorytrials.org/trial/mandala/ Asthma Adding budesonide to the albuterol reliever cut severe exacerbations by a quarter https://respiratorytrials.org/trial/tip-ex/ https://respiratorytrials.org/trial/tip-ex/ Ventilation & weaning Pressure support and T-piece breathing trials produced the same ventilator-free days https://respiratorytrials.org/trial/increase/ https://respiratorytrials.org/trial/increase/ Pulmonary hypertension Inhaled treprostinil improved walk distance in PH due to interstitial lung disease https://respiratorytrials.org/trial/navigator/ https://respiratorytrials.org/trial/navigator/ Asthma Tezepelumab halved exacerbations in severe asthma, including in patients with low eosinophils https://respiratorytrials.org/trial/recovery-dexamethasone/ https://respiratorytrials.org/trial/recovery-dexamethasone/ COVID-19 Dexamethasone reduced mortality in COVID-19 patients needing oxygen, and not in those who did not https://respiratorytrials.org/trial/remap-cap-il-6/ https://respiratorytrials.org/trial/remap-cap-il-6/ COVID-19 IL-6 receptor blockade improved organ support-free days and survival in critical COVID-19 https://respiratorytrials.org/trial/remap-cap-anticoagulation/ https://respiratorytrials.org/trial/remap-cap-anticoagulation/ COVID-19 Full-dose anticoagulation did not help critically ill COVID-19 patients